Материалов:
1 081 645

Репозиториев:
30

Авторов:
761 409

По вашему запросу найдено документов: 171182

Страница 1 из 17119

Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (covid-19): Focus on interleukin 6
Nasonov E.L.
and may be a stage of COVID-19 progression. A premium is placed to interleukin-6 (IL-6) in the spectrum
Fundamental basis of covid-19 pathogenesis [Najznačajnije osnove patogeneze covid-19]
Bolevich S.B.
into target cells that have angi-otensin converting enzyme type II receptors. The virus enters the body
The role of Interleukin 6 inhibitors in therapy of severe COVID-19
Nasonov E.
. Interleukin-6 (IL-6) plays an important role in the pathogenesis of CSS. The significant role of IL-6
Genetic dissection of host immune response in pneumonia development and progression
Smelaya T.V.
studied common polymorphisms in the genes of proinflammatory cytokines (IL6 rs1800795, IL8 rs4073, IL1B rs
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning
Shoenfeld Y.
interleukin 6
BOB.1 controls memory B-cell fate in the germinal center reaction
Levels M.J.
and functional characteristics of Bmem. Mechanistically, overexpression of BOB.1 drives ABF1 and suppresses BCL6
Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience
Zagrebneva A.I., Simonova E.N., Mezenova T.V., Burmistrova N.B., Gavrikova Yu.A., Dolgov V.V., Morozova E.O., Kodzeva Zh.M., Sapogina K.S.
(RA) switched from other interleukin 6 receptor in-hibitors (iIL6R) for non-medical reasons. Patients
Interleukin-6 is a potential target for a correction of endothelial dysfunction associated with low-grade systemic inflammation
Kostina, D. A., Pokrovskaya, T. G., Beskhmelnitsyna, E. A.
diseases. To study the endothelium protective effects of anti-IL-6 receptor monoclonal antibodies
Inhibitor of hyaluronic acid synthesis 4-methylumbelliferone as an anti-inflammatory modulator of lps-mediated astrocyte responses
Chistyakov D.V., Nikolskaya A.I., Goriainov S.V., Astakhova A.A., Sergeeva M.G.
with and without 4-MU and gene expression levels of inflammatory (interleukins 1β, (IL-1β), 6, (IL-6), tumor
Temporal clinical and laboratory response to interleukin-6 receptor blockade with tocilizumab in 89 hospitalized patients with covid-19 pneumonia
Fomina D.S.
to the interleukin-6 receptor. Results: Clinical and laboratory evidence of improvement was evident when baseline

Страница 1 из 17119

Фасеты

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core